Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 multiple ascending dose and proof-of-concept study of XTMAB-16 in pulmonary sarcoidosis
2022-502877-41-01Phase 2Authorised
- Sponsor
- Xentria
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised trial in pulmonary sarcoidosis comparing XTMAB-16 plus background corticosteroid taper with Placebo plus background corticosteroid taper (2 arms). Primary endpoints: Safety and pharmacokinetics, Pharmacodynamics, immunogenicity, and steroid reduction and 3 more. Planned start Sep 2024; status: authorised.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2022-502877-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502877-41-01.